Immunotherapy in Bladder Cancer

Initial Keytruda showed consistent antitumor activity and safety in patients with advanced bladder cancer ineligible for platinum-based chemotherapy.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

The use of prophylactic tranexamic acid didn't lead to a reduction in blood transfusion for patients undergoing open radical cystectomy for bladder cancer.

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, does not affect other indications of the therapy.